エボラウイルスワクチンの世界市場

エボラウイルスワクチンの世界市場は2030年までに2億6,990万米ドルに達する見込み

2024年に1億8,930万米ドルと推定されるエボラウイルスワクチンの世界市場は、分析期間2024-2030年にCAGR 6.1%で成長し、2030年には2億6,990万米ドルに達すると予測されます。レポートで分析されているセグメントの 1 つである cAd3-ZEBOV ワクチンは、分析期間までにCAGR 6.9%を記録し、1億9,890万米ドルに達すると予想されています。 rVSV-ZEBOVワクチン・セグメントの成長率は、分析期間中CAGR 3.9%と推定されます。

米国市場は5,160万米ドルと推定される一方、中国はCAGR 9.8％で成長すると予測される

米国のエボラウイルスワクチン市場は、2024年には5,160万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに5,560万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは9.8%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.9％と6.0％と予測されています。欧州では、ドイツがCAGR 4.0%で成長すると予測されています。

世界のエボラウイルスワクチン市場- 主要動向と促進要因のまとめ

エボラウイルスワクチンの開発が依然として世界の優先課題である理由とは？

エボラウイルス病（EVD）は、依然として世界で最も致死率の高いウイルス感染症の一つであり、サハラ以南のアフリカやその他の地域で定期的に発生し、公衆衛生上の大きな脅威となっています。フィロウイルス科に属するこのウイルスは、高い致死率（しばしば50％を超える）を伴う重篤な出血熱を引き起こし、過去20年間に何度も流行を引き起こしてきました。公衆衛生対策による流行の封じ込めは改善されたもの、ウイルスの高い伝染率と人獣共通感染症的性質は、強力な世界的ワクチン兵器の必要性を強調し続けています。

2019年にMerck社のErvebo（rVSV-ZEBOV）のようなワクチンが承認されたことは、エボラ出血熱に対する世界の対応において画期的な出来事でした。しかし、スーダンやブンディブギョの亜種を含むこのウイルスの複数の株は、より広範な防御が可能な多価ワクチンの開発を進めています。ウガンダとコンゴ民主共和国での最近の再燃は、備蓄の拡大とワクチンパイプラインの多様化に対する世界保健機関とワクチン開発者の緊急性を再燃させました。WHO、CEPI、Gaviなどの組織は、より広範なパンデミック対策戦略の一環として、ワクチンの入手しやすさと公平な配備を優先しています。

エボラワクチンの最新技術と展開とは？

エボラ出血熱に対するワクチンの技術革新は多方面で進んでいます。主要なライセンス製品であるErveboは、水疱性口内炎ウイルス（VSV）をベクターとする弱毒化組み換え生ワクチンであり、即効性の免疫力を提供するため、アウトブレイク時のリングワクチン接種に理想的です。Johnson & JohnsonのZabdeno/Mvabea2回接種レジメンは、アデノウイルスとMVAベクターを利用したもので、接種期間は長くなるもの、より広範な株に対する予防効果があります。これらのプラットフォームは現在、アクセス拡大や関連ウイルスに対する交差防御について評価中です。

COVID-19ワクチン開発で見られた技術的成功を反映し、mRNA、DNA、ナノ粒子をベースとした新しい候補が検討されています。研究者たちは、厳しいコールドチェーン要件がない遠隔地や低資源環境での使用に適した耐熱性ワクチンの開発を目指しています。さらに、皮内パッチや点鼻スプレーなど、針を使わないデリバリーシステムは、アウトブレイクシナリオにおいて、よりスケーラブルで現場に適した展開をサポートするため、前臨床研究中です。これらの進歩は、エボラワクチンを効果的なものにするだけでなく、緊急時の集団予防接種に実用的なものにしようとする世界の動きを反映しています。

世界な保健システムとパートナーシップは、ワクチンへのアクセスをどのように形成しているのか？

世界の公衆衛生機関、政府、NGOは、エボラワクチンの配布戦略の形成に深く関わっています。WHOとユニセフは、Erveboの緊急備蓄を作成し、アウトブレイク地帯での配備ロジスティクスが迅速かつうまく調整されるよう取り組んでいます。ワクチンアライアンスであるGaviは、調達資金を提供し、エボラワクチンをリスク国の国家準備計画に組み込む支援を行っています。同時にCEPIは、次世代ワクチンの候補に資金を提供し、将来のアウトブレイクにおける迅速なスケールアップのための「100日対応」モデルの確立を目指しています。

規制当局は、WHOの緊急使用リスト（EUL）、FDAの画期的治療薬指定、EMAのPRIMEスキームなどのメカニズムを通じて、ワクチンの承認を加速させる積極的な役割を果たしています。これと並行して、製薬会社は現地製造業者や世界保健機関とパートナーシップを結び、地域の生産能力を構築し、ラスト・マイル・デリバリーを改善しています。こうした努力にもかかわらず、ワクチン接種のためらい、政情不安、未発達のヘルスケア・インフラなどの課題は残っており、克服するには国際的な協調対応が必要です。

エボラワクチン市場の成長と戦略的投資の原動力は？

エボラウイルスワクチン市場の成長の原動力は、ウイルスの進化、アウトブレイク頻度の上昇、ワクチン・プラットフォーム技術の進歩に関連するいくつかの要因です。流行地域におけるエボラ出血熱の予測不能な再流行や、異なるウイルス株の出現により、世界保健コミュニティはより柔軟で幅広いスペクトルのワクチンへの投資を余儀なくされています。ベクターベースおよびmRNAワクチン・プラットフォームの技術的進歩により、開発サイクルの迅速化と多価製剤への適応性の向上が可能になりつつあります。こうした技術革新は、発生時の対応から流行時の事前準備へのシフトを後押ししています。

また、最前線のヘルスケア従事者、軍人、高リスク地域で活動する人道支援スタッフに対する曝露前予防への注目の高まりにより、最終用途の需要も拡大しています。特に米国BARDA、EUのHorizonプログラム、ゲイツ財団のような慈善団体による政府およびドナーからの資金援助が、ワクチンの研究開発と備蓄拡大に拍車をかけています。さらに、COVID-19、マールブルグ・ウイルス、その他の新興病原体と並んで、エボラ出血熱ワクチン戦略がより広範な世界・ヘルス・セキュリティの枠組みに統合されたことで、長期的な制度的支援が確保されています。これらの市場促進要因を総合すると、エボラウイルスワクチンは今後10年間、持続的かつ戦略的に重要な市場であるといえます。

セグメント

ワクチンタイプ（cAd3-ZEBOV, rVSV-ZEBOV）;菌株タイプ（Zaire, Sudan, Tai Forest, Reston, Bundibugyo Virus）;流通チャネル（病院薬局,小売薬局,オンライン薬局）;エンドユーザー（病院,在宅医療,専門クリニック,外来手術センター,その他のエンドユーザー）

調査対象企業の例（全34社）

• Bavarian Nordic A/S
• BioCryst Pharmaceuticals, Inc.
• Emergent BioSolutions Inc.
• GeoVax Labs, Inc.
• GlaxoSmithKline plc
• Immunovaccine Inc.（IMV Inc.）
• Inovio Pharmaceuticals, Inc.
• Johnson & Johnson
• Mapp Biopharmaceutical, Inc.
• Merck & Co., Inc.
• NewLink Genetics Corporation
• Novavax, Inc.
• Okairos AG
• Profectus BioSciences, Inc.
• Protein Sciences Corporation
• Sanofi S.A.
• Sarepta Therapeutics, Inc.
• Vaxart, Inc.
• VBI Vaccines Inc.
• Zydus Cadila

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Ebola Virus Vaccines Market to Reach US$269.9 Million by 2030

The global market for Ebola Virus Vaccines estimated at US$189.3 Million in the year 2024, is expected to reach US$269.9 Million by 2030, growing at a CAGR of 6.1% over the analysis period 2024-2030. cAd3-ZEBOV Vaccine, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$198.9 Million by the end of the analysis period. Growth in the rVSV-ZEBOV Vaccine segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$51.6 Million While China is Forecast to Grow at 9.8% CAGR

The Ebola Virus Vaccines market in the U.S. is estimated at US$51.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$55.6 Million by the year 2030 trailing a CAGR of 9.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Ebola Virus Vaccines Market - Key Trends & Drivers Summarized

Why Is the Development of Ebola Virus Vaccines Still a Global Priority?

Ebola virus disease (EVD) remains one of the world’s most lethal viral infections, with periodic outbreaks posing major public health threats in sub-Saharan Africa and beyond. The virus, part of the Filoviridae family, causes severe hemorrhagic fever with high fatality rates-often exceeding 50%-and has led to multiple epidemics over the past two decades, the most significant being the 2014-2016 West African outbreak. While outbreak containment through public health measures has improved, the high contagion rate and zoonotic nature of the virus continue to underscore the need for a robust global vaccine arsenal.

The approval of vaccines like Merck’s Ervebo (rVSV-ZEBOV) in 2019 was a milestone in the global response to Ebola. However, the virus's multiple strains-including Sudan and Bundibugyo variants-have driven the ongoing development of multivalent vaccines capable of broader protection. Recent flare-ups in Uganda and the Democratic Republic of Congo have reignited urgency among global health agencies and vaccine developers to expand stockpiles and diversify the vaccine pipeline. Organizations such as the WHO, CEPI, and Gavi are prioritizing vaccine accessibility and equitable deployment as part of the broader pandemic preparedness strategy.

What Are the Latest Advances in Ebola Vaccine Technology and Deployment?

Vaccine innovation for Ebola is progressing on multiple fronts. The leading licensed product, Ervebo, is a live attenuated, recombinant vaccine using vesicular stomatitis virus (VSV) as a vector, which provides fast-acting immunity-making it ideal for ring vaccination during outbreaks. Johnson & Johnson’s two-dose Zabdeno/Mvabea regimen, utilizing adenovirus and MVA vectors, offers broader strain protection, albeit with a longer immunization timeline. These platforms are now being evaluated for expanded access use and cross-protection against related viruses.

New candidates are being explored based on mRNA, DNA, and nanoparticle-based platforms, mirroring the technological success seen during COVID-19 vaccine development. Researchers are aiming to create thermostable vaccines suitable for use in remote, low-resource environments without stringent cold chain requirements. Additionally, needle-free delivery systems, such as intradermal patches and nasal sprays, are under preclinical investigation to support more scalable and field-friendly deployment in outbreak scenarios. These advancements reflect a global push to make Ebola vaccines not only effective but also practical for mass immunization efforts during emergencies.

How Are Global Health Systems and Partnerships Shaping Vaccine Accessibility?

Global public health agencies, governments, and NGOs are deeply involved in shaping Ebola vaccine distribution strategies. WHO and UNICEF have created emergency stockpiles of Ervebo and are working to ensure deployment logistics in outbreak zones are rapid and well-coordinated. Gavi, the Vaccine Alliance, is funding procurement and helping integrate Ebola vaccines into national preparedness plans in at-risk countries. Simultaneously, CEPI is funding next-generation candidates and aiming to establish a “100-day response” model for rapid scale-up in future outbreaks.

Regulatory agencies are playing a proactive role in accelerating vaccine approvals through mechanisms like the WHO Emergency Use Listing (EUL), FDA Breakthrough Therapy Designation, and EMA PRIME scheme. In parallel, pharmaceutical companies are entering partnerships with local manufacturers and global health bodies to build regional production capacity and improve last-mile delivery. Despite these efforts, challenges remain-including vaccine hesitancy, political instability, and underdeveloped healthcare infrastructure-which require coordinated international responses to overcome.

What Is Driving Growth and Strategic Investment in the Ebola Vaccine Market?

The growth in the Ebola virus vaccines market is driven by several factors related to viral evolution, rising outbreak frequency, and advancements in vaccine platform technologies. The unpredictable resurgence of Ebola in endemic regions and the emergence of distinct viral strains have compelled the global health community to invest in more flexible, broad-spectrum vaccines. Technological progress in vector-based and mRNA vaccine platforms is enabling faster development cycles and improved adaptability for multivalent formulations. These innovations are supporting a shift from reactive outbreak response to proactive epidemic preparedness.

End-use demand is also expanding due to increased focus on pre-exposure prophylaxis for frontline healthcare workers, military personnel, and humanitarian staff operating in high-risk areas. Government and donor funding, particularly from the U.S. BARDA, the EU Horizon program, and philanthropic sources like the Gates Foundation, is fueling vaccine R&D and stockpile expansion. Moreover, the integration of Ebola vaccine strategies into broader global health security frameworks-alongside COVID-19, Marburg virus, and other emerging pathogens-is ensuring long-term institutional support. These drivers collectively point to a sustained and strategically vital market trajectory for Ebola virus vaccines over the coming decade.

SCOPE OF STUDY:

The report analyzes the Ebola Virus Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vaccine Type (cAd3-ZEBOV, rVSV-ZEBOV); Strain Type (Zaire, Sudan, Tai Forest, Reston, Bundibugyo Virus); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); End-Use (Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Bavarian Nordic A/S
• BioCryst Pharmaceuticals, Inc.
• Emergent BioSolutions Inc.
• GeoVax Labs, Inc.
• GlaxoSmithKline plc
• Immunovaccine Inc. (IMV Inc.)
• Inovio Pharmaceuticals, Inc.
• Johnson & Johnson
• Mapp Biopharmaceutical, Inc.
• Merck & Co., Inc.
• NewLink Genetics Corporation
• Novavax, Inc.
• Okairos AG
• Profectus BioSciences, Inc.
• Protein Sciences Corporation
• Sanofi S.A.
• Sarepta Therapeutics, Inc.
• Vaxart, Inc.
• VBI Vaccines Inc.
• Zydus Cadila

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Ebola Virus Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increased Global Preparedness for Zoonotic Outbreaks Drives Investment in Ebola Vaccine Platforms
  • WHO Prequalification and Emergency Use Authorizations Accelerate Market Access for Leading Candidates
  • Advances in Viral Vector Platforms Propel Development of Next-Generation Ebola Vaccines
  • Government Stockpiling Initiatives Sustain Long-Term Procurement for Biodefense Applications
  • Strategic Partnerships With African Governments Enhance Local Distribution and Deployment Capacity
  • Growing Role of mRNA Technology in Infectious Disease Control Expands Ebola Vaccine Pipeline Options
  • Global Health Funding From GAVI and CEPI Strengthens R&D in Pandemic-Preparedness Vaccines
  • Focus on Multivalent Vaccine Development Supports Cross-Protection Against Emerging Strains
  • Data Sharing From Clinical Trials Across Continents Enables Real-World Effectiveness Validation
  • Vaccine Acceptance Campaigns Improve Uptake in High-Risk, Vaccine-Hesitant Communities
  • Stability Improvements in Lyophilized Formulations Increase Shelf Life for Field Use
  • Inclusion in National Immunization Programs Expands Baseline Market for Preventive Doses
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Ebola Virus Vaccines Market Analysis of Annual Sales in US$ for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for Ebola Virus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for cAd3-ZEBOV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for cAd3-ZEBOV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for rVSV-ZEBOV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for rVSV-ZEBOV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 15: World 6-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Homecare by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 17: World 6-Year Perspective for Homecare by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 18: World Recent Past, Current & Future Analysis for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 19: World 6-Year Perspective for Specialty Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 21: World 6-Year Perspective for Ambulatory Surgery Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 23: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 24: World Recent Past, Current & Future Analysis for Zaire by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 25: World 6-Year Perspective for Zaire by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Sudan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 27: World 6-Year Perspective for Sudan by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 28: World Recent Past, Current & Future Analysis for Tai Forest by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 29: World 6-Year Perspective for Tai Forest by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 30: World Recent Past, Current & Future Analysis for Reston by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 31: World 6-Year Perspective for Reston by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Bundibugyo Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 33: World 6-Year Perspective for Bundibugyo Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Ebola Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 34: USA Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 35: USA 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 36: USA Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 37: USA 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 40: USA Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 41: USA 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• CANADA
  • TABLE 42: Canada Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 43: Canada 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 46: Canada Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 47: Canada 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 48: Canada Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 49: Canada 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• JAPAN
  • Ebola Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 52: Japan Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 53: Japan 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 54: Japan Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 55: Japan 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• CHINA
  • Ebola Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 58: China Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 59: China 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 60: China Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 61: China 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 64: China Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 65: China 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• EUROPE
  • Ebola Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 66: Europe Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 67: Europe 6-Year Perspective for Ebola Virus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 70: Europe Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 71: Europe 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 72: Europe Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 73: Europe 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• FRANCE
  • Ebola Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 76: France Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 77: France 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 78: France Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 79: France 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 80: France Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 82: France Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 83: France 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• GERMANY
  • Ebola Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 84: Germany Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 85: Germany 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Germany 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 88: Germany Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 89: Germany 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 90: Germany Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 91: Germany 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• ITALY
  • TABLE 92: Italy Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Italy 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 94: Italy Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 95: Italy 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 96: Italy Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 97: Italy 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• UNITED KINGDOM
  • Ebola Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 100: UK Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 101: UK 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 102: UK Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 103: UK 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 104: UK Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 105: UK 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 106: UK Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 107: UK 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• SPAIN
  • TABLE 108: Spain Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 109: Spain 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 110: Spain Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Spain 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 112: Spain Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 113: Spain 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 114: Spain Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 115: Spain 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• RUSSIA
  • TABLE 116: Russia Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Russia 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 118: Russia Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 119: Russia 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 120: Russia Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 121: Russia 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 122: Russia Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Russia 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 124: Rest of Europe Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 125: Rest of Europe 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 126: Rest of Europe Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 127: Rest of Europe 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Rest of Europe 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 130: Rest of Europe Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 131: Rest of Europe 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• ASIA-PACIFIC
  • Ebola Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 132: Asia-Pacific Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 133: Asia-Pacific 6-Year Perspective for Ebola Virus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
  • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Asia-Pacific 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 136: Asia-Pacific Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 137: Asia-Pacific 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 138: Asia-Pacific Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 139: Asia-Pacific 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Asia-Pacific 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• AUSTRALIA
  • Ebola Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 142: Australia Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 143: Australia 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 144: Australia Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 145: Australia 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 146: Australia Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Australia 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 148: Australia Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 149: Australia 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• INDIA
  • Ebola Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 150: India Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 151: India 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 152: India Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 153: India 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 154: India Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 155: India 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 156: India Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 157: India 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• SOUTH KOREA
  • TABLE 158: South Korea Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 159: South Korea 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 160: South Korea Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 161: South Korea 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 162: South Korea Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 163: South Korea 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 164: South Korea Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 165: South Korea 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 166: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 167: Rest of Asia-Pacific 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 168: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 169: Rest of Asia-Pacific 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 170: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Rest of Asia-Pacific 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 172: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 173: Rest of Asia-Pacific 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• LATIN AMERICA
  • Ebola Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 174: Latin America Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 175: Latin America 6-Year Perspective for Ebola Virus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
  • TABLE 176: Latin America Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Latin America 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 178: Latin America Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 179: Latin America 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 180: Latin America Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 181: Latin America 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 182: Latin America Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Latin America 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• ARGENTINA
  • TABLE 184: Argentina Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 185: Argentina 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 186: Argentina Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 187: Argentina 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 188: Argentina Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Argentina 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 190: Argentina Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 191: Argentina 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• BRAZIL
  • TABLE 192: Brazil Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 193: Brazil 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 194: Brazil Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Brazil 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 196: Brazil Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 197: Brazil 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 198: Brazil Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 199: Brazil 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• MEXICO
  • TABLE 200: Mexico Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Mexico 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 202: Mexico Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 203: Mexico 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 204: Mexico Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 205: Mexico 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 206: Mexico Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Mexico 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 208: Rest of Latin America Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 209: Rest of Latin America 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 210: Rest of Latin America Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 211: Rest of Latin America 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 212: Rest of Latin America Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Rest of Latin America 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 214: Rest of Latin America Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 215: Rest of Latin America 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• MIDDLE EAST
  • Ebola Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 216: Middle East Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 217: Middle East 6-Year Perspective for Ebola Virus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
  • TABLE 218: Middle East Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Middle East 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 220: Middle East Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 221: Middle East 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 222: Middle East Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 223: Middle East 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 224: Middle East Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Middle East 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• IRAN
  • TABLE 226: Iran Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 227: Iran 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 228: Iran Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 229: Iran 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 230: Iran Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Iran 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 232: Iran Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 233: Iran 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• ISRAEL
  • TABLE 234: Israel Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 235: Israel 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 236: Israel Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Israel 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 238: Israel Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 239: Israel 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 240: Israel Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 241: Israel 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• SAUDI ARABIA
  • TABLE 242: Saudi Arabia Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Saudi Arabia 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 244: Saudi Arabia Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 245: Saudi Arabia 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 246: Saudi Arabia Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 247: Saudi Arabia 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 248: Saudi Arabia Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Saudi Arabia 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 250: UAE Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 251: UAE 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 252: UAE Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 253: UAE 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 254: UAE Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 255: UAE 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 256: UAE Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 257: UAE 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 258: Rest of Middle East Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 259: Rest of Middle East 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 260: Rest of Middle East Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Middle East 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 262: Rest of Middle East Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 263: Rest of Middle East 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 264: Rest of Middle East Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 265: Rest of Middle East 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030
• AFRICA
  • Ebola Virus Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 266: Africa Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Vaccine Type - cAd3-ZEBOV and rVSV-ZEBOV - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Africa 6-Year Perspective for Ebola Virus Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for cAd3-ZEBOV and rVSV-ZEBOV for the Years 2025 & 2030
  • TABLE 268: Africa Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 269: Africa 6-Year Perspective for Ebola Virus Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
  • TABLE 270: Africa Recent Past, Current & Future Analysis for Ebola Virus Vaccines by End-Use - Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 271: Africa 6-Year Perspective for Ebola Virus Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, Homecare, Specialty Clinics, Ambulatory Surgery Centers and Other End-Uses for the Years 2025 & 2030
  • TABLE 272: Africa Recent Past, Current & Future Analysis for Ebola Virus Vaccines by Strain Type - Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Africa 6-Year Perspective for Ebola Virus Vaccines by Strain Type - Percentage Breakdown of Value Sales for Zaire, Sudan, Tai Forest, Reston and Bundibugyo Virus for the Years 2025 & 2030

IV. COMPETITION